Ikena Oncology
Biotechnology, 645 Summer St Ste 101, Boston, Massachusetts, 02210, United States, 51-200 Employees
Phone Number: 18*********
Who is IKENA ONCOLOGY
Ikena is a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Our programs focus on key...
Read More
-
Headquarters: 645 Summer St Ste 101, Boston, Massachusetts, 02210, United States
-
Date Founded: 2016
-
Employees: 51-200
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 54 |
Show More
Does something look wrong? Fix it. | View contact records from IKENA ONCOLOGY
Ikena Oncology Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Ikena Oncology
Answer: Ikena Oncology's headquarters are located at 645 Summer St Ste 101, Boston, Massachusetts, 02210, United States
Answer: Ikena Oncology's phone number is 18*********
Answer: Ikena Oncology's official website is https://ikenaoncology.com
Answer: Ikena Oncology's revenue is $10 Million to $25 Million
Answer: Ikena Oncology's SIC: 2836
Answer: Ikena Oncology's NAICS: 54
Answer: Ikena Oncology has 51-200 employees
Answer: Ikena Oncology is in Biotechnology
Answer: Ikena Oncology contact info: Phone number: 18********* Website: https://ikenaoncology.com
Answer: Ikena is a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging our deep understanding of discovery chemistry, translational science, and patient-centric drug development, we have built a deep pipeline of wholly owned and partnered programs focused on genetically defined or biomarker-driven cancers, which enables us to target specific patient populations that we believe are most likely to respond to treatment with our product candidates. We have assembled an experienced and well-respected team of drug hunters, translational researchers, clinicians and entrepreneurs drawn from many of the largest innovators in biotechnology, supported by top-tier investors and partners, as well as world-class advisors, to advance and broaden our portfolio of novel, patient-directed oncology therapies.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month